aspirin and glp-1 Agents vs Aspirin: A New Era in Colorectal Cancer Prevention TrimRX | Can I Take

10.1093/ps/80.12.1671 31 WuG.FangY

Cardiovascular outcome trials evaluating novel agents that target multiple pathways including combinations of GLP-1 agonism, GIP agonism, glucagon receptor agonism and amylin analogues are ongoing and will help define the next generation of obesity treatments

Book an online consultation through Klarity Health with providers who accept insurance to discuss your eligibility and start the prior authorization process

Hormones, menopause, and brain resilience Hormones are not the whole dementia story, but they are part of the physiologic landscape

Altitude Drinks consumed at high altitudes are nearly twice as potent in their effect for the first few days until the person becomes accustomed to the elevation

The reasons for the lack of benefit of DPP-4 inhibitors on major cardiovascular outcomes could theoretically be related to the relatively short duration of follow-up in the landmark trials